Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 400

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 400
---
 candidates. Organizational Structure NLS is a Swiss stock corporation organized under the laws of Switzerland. NLS’s Swiss enterprise identification number is CHE -447.067.367. NLS’s registered and principal executive offices are located at The Circle6, Postfach, 8058 Zurich, Switzerland. NLS’s general telephone number is (41) 44 512 21 50 and its internet address is www.nlspharma.com. In April 2021, NLS formed a wholly owned subsidiary, NLS Pharmaceutics Inc., a Delaware corporation. In November 2024 NLS also formed Merger Sub, its wholly owned subsidiary, in connection with the Merger. NLS did not have any other subsidiaries as of December 31, 2024, and as of the date of this proxy statement/prospectus. Property, Plant and Equipment NLS’s principal executive office in Postfach, 8058 Zurich, Switzerland, consists of approximately 25 square meters (approximately 270 square feet) of shared office space under an indefinite term lease that may be terminated by either party with one -monthprior notice. NLS believes that its current office space is sufficient to meet its anticipated needs for the foreseeable future and is suitable for the conduct of its business; provided, however, that NLS may require additional space and facilities as its business expands. Legal Proceedings From time to time NLS may become involved in legal proceedings that arise in the ordinary course of business. During the period covered by the financial statements contained herein, NLS was not subject to any material legal proceedings that has had a material adverse effect on its financial position, except as described below. No assurance can be given that future litigation will not have a material adverse effect on NLS’s financial position. When appropriate in management’s estimation, NLS may record reserves in its financial statements for pending litigation and other claims. 200 Cambrex Corporation On December 1, 2023, NLS received a letter from Cambrex Corporation, stating that as of December 1, 2023, NLS had an overdue balance for services completed under certain proposals by and between the Company, Cambrex High Point, Inc. and Avista Pharma Solutions, Inc. in the aggregate amount of $492,723.23. On October 10, 2024, the Company successfully settled the outstanding claim through a debt purchase agreement with an accredited investor, in the amount of $200,013, which effectively resolved the creditor claim. Clinilabs,